wimo a., winblad b., stöffler a., wirth y., and möbius h. j
DESCRIPTION
Resource Ultilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer‘s Disease. Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J. Pharmacoeconomics 2003, 21 (5): 327-340. Study Design. No. of patients N = 252 (outpatients) - PowerPoint PPT PresentationTRANSCRIPT
Resource Ultilisation and Cost Analysis of
Memantine in Patients with Moderate to
Severe Alzheimer‘s Disease
Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J.
Pharmacoeconomics 2003, 21 (5): 327-340
No. of patients N = 252 (outpatients)
Diagnosis Probable Alzheimer’s disease
Design Double-blind, randomized, placebo-controlled, multicenter study
Age 50 years (mean 76)
Severity MMSE 3 – 14 (mean 7.9)GDS 5 – 6FAST 6a
Dose; duration 20 mg Memantine/day; 28 weeks
Pharmaco- Resource Utilisation in Dementia (RUD) economic analysis
Study Design
Wimo et al., Pharmacoeconomics 2003
Baseline Characteristics
No significant differences in demographics and
the severity of the disease between treatment
groups
Very high degree of mean caregiving time in this
moderate to severe AD population
Wimo et al., Pharmacoeconomics 2003
Memantine Treatment Reduces Rate of Institutionalizations
p-value analyzed by 2 test
TPP, N = 166 Patient residential status at week 28
Wimo et al., Pharmacoeconomics 2003
Memantine Placebo
Residential status N (%) N (%) p-value
Community 83 (92.2 %) 62 (81.6 %)
0.04
Institutional 7 (7.8 %) 14 (18.4%)
Memantine Treatment Reduces Monthly Caregiver Resource Utilization
* corrected for baseline characteristics (ANCOVA model)
TPP, N = 166 Mean time over 28-week study period
Wimo et al., Pharmacoeconomics 2003
Memantine Placebo Difference
(N = 90) (N = 76)
Caregiver time 413.46 455.64 52*(hours) [SD] [234.27] [232.70]
Work loss 9.81 14.05 4.24(hours) [SD] [29.60] [38.72]
Significant Reduction of Costs through Memantine Treatment
US
Do
llars
/ m
on
th
* p < 0.03, ** p < 0.01 versus placebo
Total caregiver costs Total societal costs
8400
8000
7600
7200
6800
6400
6000Memantine Memantine
*
**
Placebo Placebo
TPP, N = 166 Adjusted mean monthly costs
Wimo et al., Pharmacoeconomics 2003
Summary
* corrected for confounding effects
Caregiver time and institutionalization were the main
cost drivers
Average monthly caregiver costs were $ 824 lower in the
memantine group*
Average monthly societal costs were $ 1090 lower in the
memantine group*
Conclusion:
Memantine treatment may lead to significant cost
savings by reduction of resource utilization
Wimo et al., Pharmacoeconomics 2003